National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI

Understanding Cancer Series: Angiogenesis
< Back to Main
In English En español
    Posted: 01/28/2005    Reviewed: 09/01/2006
Page Options
Print This Page  Print This Page
Print This Document  Print This Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
View/Print PDF  View/Print PDF
View/Print PowerPoint  View/Print PowerPoint
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Office of Biorepositories and Biospecimen Research

The Nation's Investment in Cancer Research FY 2010

Report to Nation Finds Declines in Cancer Incidence, Death Rates
Slide 17 : Angiogenesis Inhibitors and Metastasis previousnext

The discovery that angiogenesis inhibitors such as endostatin can restrain the growth of primary tumors raises the possibility that such inhibitors might also be able to slow tumor metastasis.

To test this hypothesis, researchers injected several kinds of mouse cancer cells beneath the animals' skin and allowed the cells to grow for about two weeks. The primary tumors were then removed, and the animals checked for several weeks. Typically, mice developed about 50 visible tumors from individual cancer cells that had spread to the lungs prior to removal of the primary tumor. But mice treated with angiostatin developed an average of only 2-3 tumors in their lungs. Inhibition of angiogenesis by angiostatin had reduced the rate of spread (metastasis) by about 20-fold.

Angiogenesis Inhibitors and Metastasis

< Previous  |  Index  |  Next Slide >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov